These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
    Author: Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N.
    Journal: Diabetes Obes Metab; 2017 Jun; 19(6):842-849. PubMed ID: 28124820.
    Abstract:
    AIMS: To compare the cost-effectiveness of 2 glucagon-like peptide-1 (GLP-1) receptor agonists, liraglutide 1.8 mg and lixisenatide 20 µg, in the UK setting based on the LIRA-LIXI trial (NCT01973231). MATERIALS AND METHODS: Projections of costs (in 2015 pounds sterling [£]) and clinical outcomes were made over patient lifetimes using the IMS CORE Diabetes Model (IMS Health, Basel, Switzerland). The baseline cohort and treatment effects applied after initiation of GLP-1 receptor agonists were taken from the LIRA-LIXI trial. Future costs and clinical benefits were discounted at 3.5% annually. RESULTS: Liraglutide 1.8 mg was associated with improved discounted quality-adjusted life expectancy (8.87 vs 8.76 quality-adjusted life years [QALYs]) vs lixisenatide 20 µg. A greater reduction in glycated haemoglobin with liraglutide 1.8 mg led to fewer diabetes-related complications and delayed their time of onset. Liraglutide 1.8 mg was associated with increased total costs (£37 153 vs £36 174), driven by higher acquisition costs, but this was partially offset by savings from diabetes-related complications avoided (£26 969 vs £27 912). Liraglutide 1.8 mg was associated with an incremental cost-effectiveness ratio of £8901 per QALY gained vs lixisenatide 20 µg. CONCLUSIONS: Long-term projections suggest that treatment of patients with type 2 diabetes with liraglutide 1.8 mg is likely to be considered highly cost-effective compared with lixisenatide 20 µg treatment in the UK setting.
    [Abstract] [Full Text] [Related] [New Search]